Trial abstract · §3
AWARD-6 — results
Primary endpoint, absolute and relative effect where derivable, and harms as reported.
§3Results
§3.1Primary endpoint
Table 3. Primary endpoint as reported.
| Endpoint | Result as reported | Certainty |
|---|---|---|
| Change in glycated haemoglobin from baseline to week 26, dulaglutide 1.5 mg versus liraglutide 1.8 mg | Non-inferior to liraglutide 1.8 mg | High |
| Reproduced from the published report. Where the report states a confidence interval the Institute reproduces it; where it does not, none is constructed. | ||
§3.2Endpoint hierarchy
§3.3Harms as reported
Table 5. Adverse events for Dulaglutide from the safety tables the Institute holds for this compound. Where a row names a different trial as its source, the figure is from that trial and not from this one.
| Event | Active, % | Comparator, % | Source trial |
|---|---|---|---|
| Nausea | 12.4 | 5.3 | AWARD programme pooled (1.5 mg) |
| Diarrhoea | 8.9 | 5.0 | AWARD pooled |
| Vomiting | 6.0 | 2.3 | AWARD pooled |
| Abdominal pain | 6.5 | 4.7 | AWARD pooled |
| Decreased appetite | 4.9 | 1.6 | AWARD pooled |
| Acute pancreatitis | 0.1 | 0.1 | REWIND |
| Discontinuation for adverse events | 5.1 | 2.9 | AWARD pooled |
| Antibody formation | 1.6 | — | AWARD pooled; neutralising antibodies rare |
Compound Evidence Institute · CEI-TR-0081/3 · https://compoundevidence.com/trials/award-6/results/ · retrieved 30 July 2026